Our Platform 

Our proprietary, autologous fibroblast technology platform is the foundation for developing disease-modifying therapies for orphan conditions with high unmet medical needs

Creating Novel Personalized Gene Therapies for Localized Treatment

Castle Creek Biosciences’ autologous fibroblast technology uses our patented manufacturing process, which involves collecting small skin biopsies from patients, isolating cells and expanding them in culture, transducing the fibroblast cells with an integrative lentiviral vector to express a targeted protein, followed by continued expansion of the gene-modified cells in culture. In this manner, each patient is treated with cells that were cultivated from his or her own dermal tissue (i.e., autologous).


Our entire fibroblast platform is done autologously. This approach allows us to avoid many of the rejection concerns presented with allogeneic cells and results in a higher likelihood of efficacy.

John Maslowski, Chief Operating Officer

The Science of Autologous Fibroblasts

Fibroblasts, the most common cell in skin and connective tissue, are responsible for synthesizing extracellular matrix proteins, including collagen, that provide structure and support. Castle Creek Biosciences is leveraging these clinical benefits of fibroblasts as the basis of our proprietary, autologous fibroblast technology platform.

science of autologous fibroblasts

Readily Sourced from Skin

Fibroblasts are found in all skin and connective tissue and can be isolated from the skin and expanded in culture.  The ability to genetically modify fibroblasts has been well documented in scientific literature .

Functionally Critical

Fibroblasts synthesize the structural framework of tissue.

Ideal Delivery Vehicle

Fibroblasts have unique capabilities for localized (vs. systemic) delivery to gene targets in the skin and connective tissue.